| 1 | = | Malignant Breast Neoplasm | 0.23 | 100 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 673
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 547
ranking row 2569640 |
| 2 | = | Malignant Prostate Neoplasm | 0.23 | 95.7 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 317
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 258
ranking row 2569641 |
| 3 | = | Malignant Pancreatic Neoplasm | 0.22 | 91.3 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 217
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 178
ranking row 2569642 |
| 4 | = | Malignant Central Nervous System Neoplasm | 0.22 | 87 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 173
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 142
ranking row 2569643 |
| 5 | = | Malignant Bladder Neoplasm | 0.18 | 82.6 | Medium confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 79
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 67
ranking row 2569644 |
| 6 | = | Malignant Gastric Neoplasm | 0.15 | 78.3 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 168
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 146
ranking row 2569645 |
| 7 | = | Multiple Myeloma | 0.13 | 73.9 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 170
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 150
ranking row 2569646 |
| 8 | = | Skin Carcinoma | 0.12 | 69.6 | Medium confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 28
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 25
ranking row 2569647 |
| 9 | = | Malignant Ovarian Neoplasm | 0.1 | 65.2 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 145
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 132
ranking row 2569648 |
| 10 | = | Malignant Rectal Neoplasm | 0.1 | 60.9 | Medium confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 101
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 92
ranking row 2569649 |
| 11 | = | Malignant Lip and Oral Cavity Neoplasm | 0.1 | 56.5 | Medium confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 45
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 41
ranking row 2569650 |
| 12 | = | Non-Hodgkin Lymphoma | 0.09 | 52.2 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 432
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 395
ranking row 2569651 |
| 13 | = | Malignant Lung Neoplasm | 0.08 | 47.8 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 669
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 619
ranking row 2569652 |
| 14 | = | Malignant Kidney Neoplasm | 0.07 | 43.5 | Medium confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 101
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 94
ranking row 2569653 |
| 15 | = | Malignant Liver Neoplasm | 0.05 | 39.1 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 231
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 219
ranking row 2569654 |
| 16 | = | Malignant Nasopharyngeal Neoplasm | 0.05 | 34.8 | Medium confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 61
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 58
ranking row 2569655 |
| 17 | = | Malignant Thyroid Gland Neoplasm | 0.05 | 30.4 | Medium confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 43
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 41
ranking row 2569656 |
| 18 | = | Malignant Esophageal Neoplasm | 0.04 | 26.1 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 128
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 123
ranking row 2569657 |
| 19 | = | Malignant Uterine Corpus Neoplasm | 0.03 | 21.7 | Medium confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 100
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 97
ranking row 2569658 |
| 20 | = | Leukemia | -0.02 | 17.4 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 348
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 355
ranking row 2569659 |
| 21 | = | Malignant Colon Neoplasm | -0.04 | 13 | Medium confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 50
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 52
ranking row 2569660 |
| 22 | = | Hodgkin Lymphoma | -0.04 | 8.7 | Medium confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 23
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 24
ranking row 2569661 |
| 23 | = | Malignant Oropharyngeal Neoplasm | -0.08 | 4.3 | Medium confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 24
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 26
ranking row 2569662 |
| 24 | = | Malignant Cervical Neoplasm | -0.13 | 0 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- windows
- new12m
- to
- 2026-09-29
- from
- 2025-09-29
- prior12m
- to
- 2025-09-29
- from
- 2024-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- newTrials12m
- 103
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- minPriorTrials
- 20
- newTrialsPrior12m
- 118
ranking row 2569663 |